UCB adding Ra’s rare immunology assets in $2.5B takeout
Acquiring Ra helps UCB build rare disease immunology franchise, adds Boston-area research hub
UCB is looking to build its rare disease immunology franchise through its proposed $2.5 billion acquisition of Ra Pharmaceuticals -- a price that more than doubles the biotech’s valuation.
The deal would give UCB S.A. (Euronext:UCB) zilucoplan, a peptide inhibitor of C5. Last week, Ra Pharmaceuticals Inc. (NASDAQ:RARX) started testing the therapy in the Phase III RAISE